| Literature DB >> 23525238 |
Therese Liechtenstein1, Ines Dufait, Christopher Bricogne, Alessio Lanna, Joeri Pen, Karine Breckpot, David Escors.
Abstract
For T cell activation, three signals have to be provided from the antigen presenting cell; Signal 1 (antigen recognition), signal 2 (co-stimulation) and signal 3 (cytokine priming). Blocking negative co-stimulation during antigen presentation to T cells is becoming a promising therapeutic strategy to enhance cancer immunotherapy. Here we will focus on interference with PD-1/PD-L1 negative co-stimulation during antigen presentation to T cells as a therapeutic approach. We will discuss the potential mechanisms and the therapeutic consequences by which interference/inhibition with this interaction results in anti-tumour immunity. Particularly, we will comment on whether blocking negative co-stimulation provides differentiation signals to T cells undergoing antigen presentation. A major dogma in immunology states that T cell differentiation signals are given by cytokines and chemokines (signal 3) rather than co-stimulation (signal 2). We will discuss whether this is the case when blocking PD-L1/PD-1 negative co-stimulation.Entities:
Keywords: CD80; Cancer; Co-stimulation; Dendritic cell; Immunotherapy; PD-1; PD-L1
Year: 2012 PMID: 23525238 PMCID: PMC3605779 DOI: 10.4172/2155-9899.S12-006
Source DB: PubMed Journal: J Clin Cell Immunol